Biohaven (BHVN) has entered a multi-program research collaboration with Bexorg to advance next-generation therapies for central nervous system disorders, Bexorg said Tuesday.

Financial details weren't disclosed.

As part of the collaboration, Bexorg will apply its proprietary whole-brain discovery platform to support two of Biohaven's preclinical development programs, with an aim to generate detailed insights into target engagement, pharmacokinetics, pharmacodynamics, and mechanisms of action for Biohaven's investigational therapies.

Price: 16.92, Change: -0.14, Percent Change: -0.81